<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar1534</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>Elevated titers of anti-ribosomal-P antibodies in systemic lupus erythematosus</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Zandman-Goddard</snm>
               <fnm>G</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Gilburd</snm>
               <fnm>B</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Bardechevski</snm>
               <fnm>S</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>Stojanovich</snm>
               <fnm>L</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Langevitz</snm>
               <fnm>P</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A6">
               <snm>Shoenfeld</snm>
               <fnm>Y</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Center for Autoimmune Diseases and Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel</p>
            </ins>
            <ins id="I2">
               <p>Rheumatology Unit, Sackler Faculty of Medicine, Tel-Aviv University, Israel</p>
            </ins>
         </insg>
         <source>Arthritis Research &amp; Therapy</source>
         <supplement>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <sponsor>
               <note>The organizer would like to thank the following companies who have generously supported the meeting: Abbott Immunology (Main sponsor), Bristol-Myers Squibb, Schering-Plough, Wyeth, AstraZeneca, MSD, Amgen</note>
            </sponsor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <location>Glasgow, UK</location>
            <date-range>24-27 February 2005</date-range>
         </conference>
         <issn>1478-6354</issn>
         <pubdate>2005</pubdate>
         <volume>7</volume>
         <issue>Suppl 1</issue>
         <fpage>P13</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar1534</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>11</day>
               <month>1</month>
               <year>2005</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>17</day>
               <month>2</month>
               <year>2005</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2005</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Objective</p>
         </st>
         <p>Ribosomal P is located in the cytoplasm. The detection of antibodies is to the 60 kda fraction. Anti-ribosomal P antibodies are highly specific for systemic lupus erythematosus (SLE), and are detected at a 15&#8211;20% frequency according to the literature. Elevated anti-ribosomal P titers correlate with disease activity and are specifically associated with neuropsychiatric disease such as psychosis/depression. and coexist with anti-dsDNA antibodies. The aim of our study was to evaluate the frequency of anti-ribosomal P antibody titers and the correlation with manifestations in SLE patients.</p>
      </sec>
      <sec>
         <st>
            <p>Methods</p>
         </st>
         <p>Sera samples from 174 individuals were evaluated for titers of anti-ribosomal P antibodies: 77 samples from SLE patients, 22 patients with antiphospholipid syndrome (APS), 20 patients with familial Mediterranean fever, 12 patients with infections, and 43 healthy controls. Anti-ribosomal P antibody titers were tested by ELISA. Manifestations of SLE at the time of serum sampling were determined by the SLEDAI score.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>Six SLE patients (11%) harbored elevated anti-ribosomal P antibody titers. Five SLE patients were females, mean age 44.3 years (range, 18&#8211;73 years old), and the mean SLEDAI mean score was 7 (range, 3&#8211;10) indicating moderate disease. Elevated titers of anti-dsDNA were detected in 50% of SLE patients with elevated anti-ribosomal P antibodies. One patient had secondary APS. One patient with elevated titers of anti-ribosomal had renal disease and psychosis. Three patients had a rash, while none of the patients had arthritis or leukopenia. Anti-ribosomal P titers were not elevated in patients with primary APS, familial Mediterranean fever, infections, or in healthy controls.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusion</p>
         </st>
         <p>The prevalence of elevated titers of anti-ribosomal P antibodies was restricted to SLE patients. No correlation with a specific manifestation was found.</p>
      </sec>
   </bdy>
</art>
